New Alzheimer’s drug to be submitted to FDA for approval

Drug company Biogen Inc. intends to pursue regulatory approval from the Food and Drug Administration (FDA) for their experimental Alzheimer’s drug, aducanumab, based on new analyses of data from their Phase 3 clinical trials. The study results showed reduced decline in people with mild cognitive impairment and mild dementia due to Alzheimer’s disease who received the highest dose of the drug over a sufficient period of time.

Dr. Ronald Petersen, director of the Alzheimer’s Disease Research Center at Mayo Clinic, says aducanumab targets the amyloid plaques in the brain that are believed to be an essential component of Alzheimer’s disease.

More health and medical news on the Mayo Clinic News Network.

Journalists: Clean and nat sound versions of this pkg available for download at

Register (free) at

Articles You May Like

Long COVID Patient Being Assessed For Lung Transplant Says, ‘To Breathe Is A Fight’
Study finds unusual peak in RSV hospitalizations in late 2021
New statement suggests next steps to interpret incidentally identified gene variants related to heart disease
Mayo Clinic Minute: Can the MIND diet improve brain health?
‘Startling’ Cost Barriers After Abnormal Screening Mammogram

Leave a Reply

Your email address will not be published. Required fields are marked *